Article Information
History
- May 18, 2018.
Article Versions
- Version 1 (September 30, 2016 - 06:25).
- Version 2 (December 18, 2017 - 06:15).
- You are viewing Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- 1Institut de Gntique Molculaire de Montpellier, University of Montpellier, CNRS, Montpellier, France
- 2Institut de Biologie Computationnelle, 860 rue de St. Priest, 34095 Montpellier cedex 5, France
- 3Centre for Molecular Medicine and Therapeutics at the Child and Family Research Institute, Department of Medical Genetics, University of British Columbia, 980 West 28th Avenue, Room 3103, V5Z 4H4, Vancouver, BC, Canada
- 4Centre for Molecular Medicine Norway (NCMM), Nordic EMBL partnership, Faculty of Medicine, University of Oslo, Oslo, Norway
- 5Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway
- ↵*To whom correspondance should be addressed: charles.lecellier{at}igmm.cnrs.fr (CHL), anthony.mathelier{at}ncmm.uio.no (AM)
Posted May 18, 2018.
Human enhancers harboring specific sequence composition, activity, and genome organization are linked to the immune response
